Fasenra(benralizumab)
Fasenra (benralizumab) is an antibody pharmaceutical. Benralizumab was first approved as Fasenra on 2017-11-14. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. It is known to target interleukin-5 receptor subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Fasenra
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Benralizumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Fasenra | benralizumab | AstraZeneca | N-761070 RX | 2017-11-14 | 3 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fasenra | Biologic Licensing Application | 2024-09-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| asthma | EFO_0000270 | D001249 | J45 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0517 | Injection, benralizumab, 1 mg |
Clinical
Clinical Trials
112 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 1 | 1 | 19 | 6 | 24 | 51 |
| Pulmonary eosinophilia | D011657 | EFO_0007257 | J82.81 | — | — | 5 | 3 | 13 | 21 |
| Eosinophilia | D004802 | — | D72.1 | — | 2 | 6 | 2 | 6 | 14 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | 2 | 3 | — | 1 | 7 |
| Obstructive lung diseases | D008173 | — | — | 1 | 2 | 3 | — | 1 | 7 |
| Lung diseases | D008171 | EFO_0003818 | J98.4 | 1 | 2 | 3 | — | — | 6 |
| Nasal polyps | D009298 | — | J33 | — | — | 3 | — | 1 | 4 |
| Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 1 | 3 | — | — | 3 |
| Hypereosinophilic syndrome | D017681 | EFO_1001467 | D72.11 | — | 1 | 2 | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 2 |
| Polyps | D011127 | EFO_0000662 | — | — | — | 1 | — | 1 | 2 |
| Churg-strauss syndrome | D015267 | EFO_0007208 | M30.1 | — | — | 2 | — | — | 2 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | — | 1 | 2 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
| Eczema | D004485 | — | L30.9 | — | 2 | — | — | — | 2 |
| Dermatitis | D003872 | — | L30.9 | — | 2 | — | — | — | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 2 | — | — | — | 2 |
| Chronic urticaria | D000080223 | — | L50.8 | — | 1 | — | — | — | 1 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | 1 | — | — | — | 1 |
| Immune system diseases | D007154 | — | D89.9 | — | 1 | — | — | — | 1 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | — | 1 | — | — | — | 1 |
| Skin diseases | D012871 | — | L00-L99 | — | 1 | — | — | — | 1 |
| Genetic skin diseases | D012873 | — | — | — | 1 | — | — | — | 1 |
Show 6 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Benralizumab |
| INN | benralizumab |
| Description | Benralizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1742991 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB12023 |
| UNII ID | 71492GE1FX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IL5RA
IL5RA
Organism
Homo sapiens
Gene name
IL5RA
Gene synonyms
IL5R
NCBI Gene ID
Protein name
interleukin-5 receptor subunit alpha
Protein synonyms
CD125, CD125 antigen, CDw125, IL-5 receptor subunit alpha, IL-5R subunit alpha, interleukin 5 receptor type 3, interleukin 5 receptor, alpha, interleukin-5 receptor alpha chain
Uniprot ID
Mouse ortholog
Il5ra (16192)
interleukin-5 receptor subunit alpha (P21183)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Fasenra – AstraZeneca
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,018 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,643 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use